EMD527040 is a powerful and highly specific αvβ6 antagonist, exhibiting notable antifibrotic properties. It is suitable for conducting research on carcinoma and liver fibrosis.

αvβ6:6 nM (IC50)

EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC50 50 )[1].EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC 50 of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins[1].

EMD527040 (intraperitoneal?injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4) -/- mice[1]. Animal Model: Male adult Wistar rats Dosage: 20-60 mg/kg Administration: Intraperitoneal?injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation) Result: Ameliorated fibrosis progression in rodents with biliary fibrosis.